Skip to main content
Equibles

EHSI · Elite Health Systems Inc. · Metrics

Track EHSI — free

Use EHSI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EHSI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.83 At close · Oct 20
Rebalance outlook locked
Going-concern doubt — cleared Aug 19, 2026

The latest filing states the doubt was alleviated.

“Together, these factors raised substantial doubt regarding the Company’s ability to continue as a going concern at June 30, 2026. Management believes its plan alleviates the substantial doubt and that it will be successful in its planned business initiatives and will be able to continue as a going concern through at least the next twelve months.”
View the 10-Q filed Aug 19, 2026
Market Cap
$23.67M
Shares
28.52M
Volume · Oct 20 7138 Avg daily vol (18 sessions) 4301

EHSI metrics

50 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.83
Market cap
$23.67M

Price action

20 metrics
Price change (1W)
+10.7%
Price change (30D)
-2.4%
Price change (3M)
-10.8%
Price change (6M)
-33.1%
Price change (YTD)
-34.1%
Price change (1Y)
-40.7%
Trailing year
Price change (5Y)
+167.7%
52-week high
$1.50
52-week low
$0.63
Change from 52-week high
-44.7%
Change from 52-week low
+31.7%
Annualized volatility
97.2%
Annualized volatility (3M)
—
Beta
—
RSI (14D)
46.1
Price vs SMA 50
-18.5%
Price vs SMA 200
-21.5%
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
28.52M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
6.3×
reciprocal yield 15.8%
P / book
9.2
reciprocal yield 10.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-41.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
11.5%
Operating margin
-155.6%
Trailing 12 months
Net margin
-261.7%
Gross profit (TTM)
$403,000
Operating profit (TTM)
−$5.81M
Net income (TTM)
−$9.77M
Trailing 12 months
Diluted EPS (TTM)
$-0.19
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
$0.19
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.19

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$3.73M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+51.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
-20.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-380.1%
Return on assets
-249.3%
Debt / equity
—
Current ratio
1.4
EBITDA (TTM)
$1.49M
Free cash flow (TTM)
—
Quick ratio
1.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.30M
Total assets
$3.92M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$4.92M
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
$6.21M
Stock compensation (TTM)
$651,000
R&D / revenue
—
Stock compensation / revenue
17.4%

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
38 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1089815 CUSIP 90336K101 Visit website Investor relations